Repression of RUNX1 Activity by EVI1: A New Role of EVI1 in Leukemogenesis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Recurring chromosomal translocations observed in human leukemia often result in the expression of fusion proteins that are DNA-binding transcription factors. These altered proteins acquire new dimerization properties that result in the assembly of inappropriate multimeric transcription complexes that deregulate hematopoietic programs and induce leukemogenesis. Recently, we reported that the fusion protein AML1/MDS1/EVI1 (AME), a product of a t(3;21)(q26;q22) associated with chronic myelogenous leukemia and acute myelogenous leukemia, displays a complex pattern of self-interaction. Here, we show that the 8th zinc finger motif of MDS1/EVI1 is an oligomerization domain involved not only in interaction of AME with itself but also in interactions with the parental proteins, RUNX1 and MDS1/EVI1, from which AME is generated. Because the 8th zinc finger motif is also present in the oncoprotein EVI1, we have evaluated the effects of the interaction between RUNX1 and EVI1 in vitro and in vivo. We found that in vitro, this interaction alters the ability of RUNX1 to bind to DNA and to regulate a reporter gene, whereas in vivo, the expression of the isolated 8th zinc finger motif of EVI1 is sufficient to block the granulocyte colony-stimulating factor–induced differentiation of 32Dcl3 cells, leading to cell death. As EVI1 is not detected in normal bone marrow cells, these data suggest that its inappropriate expression could contribute to hematopoietic transformation in part by a new mechanism that involves EVI1 association with key hematopoietic regulators, leading to their functional impairment. [Cancer Res 2007;67(12):5658–66]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y., & Ohki, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10431 · Cited by 872 · cited 1×
“RUNX1 , first identified as one of the genes involved in the recurring 8;21 chromosomal translocation (18), is the most frequent target of a variety of genetic lesions detected in human hematopoietic disorders.”
BackgroundJousset, C., Carron, C., Boureux, A., Quang, C. T., Oury, C., Dusanter‐Fourt, I., Charon, M., Levin, J., Bernard, O., & Ghysdael, J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.1.69 · Cited by 207
Zhang, D.-E., Fujioka, K.-I., Hetherington, C. J., Shapiro, L. H., Chen, H.-M., Look, A. T., & Tenen, D. G. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.8085-8095.1994 · Cited by 199 · cited 1×
“To determine whether the transactivating property of RUNX1 is altered in the presence of EVI1, we did reporter gene assays with the M-CSFR minimal promoter, which depends on RUNX1 for activation (17).”
MethodSUV39H1 interacts with AML1 and abrogates AML1 transactivity: AML1 is methylated in vivo.
Chakraborty, S., Sinha, K. K., Senyuk, V., & Nucifora, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206600 · Cited by 71
Self-citation
Cited by
Stein, S., Ott, M. G., Schultze-Strasser, S., Jauch, A., Burwinkel, B., Kinner, A., Schmidt, M., Krämer, A., Schwäble, J., Glimm, H., et al. (2010) · Nature Medicine · doi:10.1038/nm.2088 · Cited by 716
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
Bejar, R., Levine, R., & Ebert, B. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1175 · Cited by 305
The prdm family: expanding roles in stem cells and development
Hohenauer, T., & Moore, A. W. (2012) · Development · doi:10.1242/dev.070110 · Cited by 265
“Here, we discuss some of these recent studies, which REVIEW Development 139 (13) Factor Intrinsic enzymatic activity Binding to chromatin modifiers Other co-repressors and binding partners Prdm1 G9a (Gyory et al., 2004), Lsd1 (Su et al., 2009), Hdac2 (Yu et al., 2000), Prmt5 (Ancelin et al., 2006) Groucho family (Tle1…”
PRDM proteins: important players in differentiation and disease
Fog, C. K., Galli, G. G., & Lund, A. H. (2012) · BioEssays · doi:10.1002/bies.201100107 · Cited by 201
“PRDMs’ molecular mechanisms in transcriptional regulation Name Common alias HMT activity (in complex) Consensus sequence Binding partners PRDM1 BLIMP1 (Prmt5 H2AR3me2s, H4R3me2s [14]), (G9a H3K9me2 [9]) Yes [99] G9a [9], HDAC2 [13], IRF4 [100], LSD1 [15], PRMT5 [14], TLE1, TLE2 [18] PRDM2 RIZ1/2 H3K9me2 [6] ER [101],…”
Metadata
- Authors
- Senyuk, V., Sinha, K. K., Li, D., Rinaldi, C. R., Yanamandra, S., & Nucifora, G.
- Venue
- Cancer Research
- Published
- 2007-06-15
- Volume
- 67
- Issue
- 12
- Pages
- 5658-5666
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2010572463
- Cited by
- 64
- References
- 4
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Repression of RUNX1 Activity by EVI1: A New Role of EVI1 in Leukemogenesis. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-3962
- The paper
- Senyuk, V., Sinha, K. K., Li, D., Rinaldi, C. R., Yanamandra, S., & Nucifora, G. (2007). Repression of RUNX1 Activity by EVI1: A New Role of EVI1 in Leukemogenesis. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-3962
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.